iRhythm Technologies, Inc. (NASDAQ:IRTC) shared operational highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conference.
Revenue for 2025 is expected to exceed previous guidance, driven by a strong fourth quarter.
For 2026, revenue is forecasted to grow 17-18% year-over-year with an anticipated adjusted EBITDA margin of 11.5% to 12.5%.
Record Revenue Volume
Full year 2025 revenue expected to exceed high end of guidance driven by Q4 performance.
Revenue Growth Outlook
2026 revenue projected to be $870-880 million with 17-18% growth year-over-year.
Clinical Superiority Evidence
Recent real-world data reinforces Zio LTCM clinical superiority, supporting market expansion.
Expansion Plans
Company aims to deepen penetration in primary care, expand into new markets, and focus on international growth.
- iRhythm had a transformative year in 2025 with significant revenue growth and free cash flow positivity for the first time.
- The company's clinical evidence program supports the clinical superiority of Zio LTCM and paves the way for market expansion and growth.
iRhythm Technologies is well-positioned for growth in 2026, with multiple catalysts driving expansion and profitability. The company's focus on innovation and market penetration signals a positive outlook for the future.